Chinese biopharmaceutical startup Gracell Biotechnologies Co., Ltd recently announced the completion of a US$100 million Series C financing. This round of financing was led by Wellington Management Company, OrbiMed and Morningside Ventures. New investors participating in this round also include Vivo Capital. Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP […]
CAR-T Biotech Firm Gracell Completes $100 Million Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Visit the original source and full text: China Money Network